Trials / Completed
CompletedNCT02220725
A Study in Older Subject to Evaluate the Safety and Ability of Andexanet Alfa to Reverse the Anticoagulation Effect of Rivaroxaban
A Phase 3 Randomized, Double-blind, Placebo-controlled Study in Older Subjects to Assess Safety and the Reversal of Rivaroxaban Anticoagulation With Intravenously Administered Andexanet Alpha
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 80 (actual)
- Sponsor
- Portola Pharmaceuticals · Industry
- Sex
- All
- Age
- 50 Years – 75 Years
- Healthy volunteers
- Accepted
Summary
The purpose of this study is to evaluate the ability of Andexanet Alfa to reverse the anticoagulation effect of Rivaroxaban.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | Andexanet | |
| OTHER | Placebo |
Timeline
- Start date
- 2014-05-01
- Primary completion
- 2015-08-01
- Completion
- 2015-08-01
- First posted
- 2014-08-20
- Last updated
- 2023-02-10
- Results posted
- 2018-09-25
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT02220725. Inclusion in this directory is not an endorsement.